Sobi no longer in acquisition talks
This article was originally published in Scrip
Swedish Orphan Biovitrum (Sobi) says its board of directors has terminated discussions with its mystery potential buyer. It confirmed on 27 April that it had been approached regarding an acquisition. Likely suitors were touted as Biogen, Pfizer, Baxter or Novo Nordisk. Sobi said it would now continue to focus on preparations for the planned launch of Elocta (antihemophilic Factor (Recombinant), Fc Fusion Protein) and Alprolix (coagulation Factor IX (recombinant), Fc Fusion Protein) and on building value through its portfolio.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.